A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

PURPOSE: To evaluate the toxicity profile, pharmacologic, and biological properties of 3-pyridylmethyl N-{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate (MS-275), a histone deacetylase inhibitor, when administered orally on three different dosing schedules. EXPERIMENTAL DESIGN: Patients with advanced...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Gore, Lia, Rothenberg, Mace L., O'Bryant, Cindy L., Schultz, Mary Kay, Sandler, Alan B., Coffin, Denise, McCoy, Candice, Schott, Astrid, Scholz, Catherine, Eckhardt, S. Gail
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2813676/
https://ncbi.nlm.nih.gov/pubmed/18579665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-1461
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires